Robert A. Ingram

This article is a stub. You can help by expanding it.

Biographical Information

"Mr. Ingram serves as the Lead Director on the boards of Valeant Pharmaceuticals and Cree, Inc. He is also a member of the Board of Directors of Regeneron Pharmaceuticals, Inc. and is Chairman of Viamet, a private company focused on anti-infective research." [1]

"Bob Ingram joined Hatteras Venture Partners as a General Partner on January 24, 2007. He began his career in the pharmaceutical industry as a professional sales representative and rose through a series of roles with increasing responsibility to ultimately become CEO/Chairman of GlaxoWellcome. He co-led the merger and integration that formed GlaxoSmithKline, the world’s second largest pharmaceutical company. Upon reaching the mandatory retirement age of 60, Bob was asked by the Board to serve as Vice Chairman Pharmaceuticals, GSK, which he did until January 1, 2010, at which time he became Strategic Advisor to the Chief Executive Officer, GlaxoSmithKline plc.

"Bob serves on the Board of Directors of portfolio company PhaseBio Pharmaceuticals, Inc. He graduated from Eastern Illinois University with a BS degree in Business Administration.

"Bob serves as Chairman of Elan Corporation plc. and as Lead Director of Valeant Pharmaceuticals International and Cree, Inc. He is also a member of the Board of Directors of Edwards Lifesciences Corporation.

"In addition to his professional responsibilities, Bob was asked by former US President George H.W. Bush to form and chair the CEO Roundtable on Cancer. He is a member of numerous other civic and professional organizations. In January 2004, Bob was awarded the Martin Luther King, Jr. Legacy Award for International Service. On July 27, 2006, he was appointed by President George W. Bush to the National Institutes of Health, National Cancer Advisory Board.

"Bob is a member of the boards for the James B. Hunt Jr. Institute for Educational Leadership and Policy, H. Lee Moffitt Cancer Center, CEO Roundtable on Cancer, Research Triangle Institute and Chairman, GlaxoSmithKline Foundation. He serves as Chairman of Research Triangle Foundation of North Carolina and is on the Advisory Board, Leonard D. Schaeffer Center for Health Policy & Economics, University of Southern California."

• Senior advisor, Global Healthcare Opportunities

Affiliations

• OSI Pharmaceuticals (which since 2010 has been owned by Astellas Pharma )
• Wachovia
• Project HOPE

Resources and articles

Related Sourcewatch

• Hatteras has an outstanding scientific advisory board chaired by Herb Boyer, the founder of Genentech